CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
Clarithromycin +1 moredrug
Likely dose
Clarithromycin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00835692
NCT00835692Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Fasting COnditions

Teva Pharmaceuticals USA·interventional·Posted Feb 4, 2009·Updated Aug 20, 2024

In Brief

A Phase 1 clinical trial evaluating Clarithromycin and Biaxin® for Healthy. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 4, 2009
Enrollment StartSep 1, 2002
Primary CompletionSep 1, 2002
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago

Interventions

Clarithromycindrug

500 mg Tablet

Biaxin®drug

500 mg Tablet